Matchpoint Therapeutics Raises $150M Series B for Autoimmune Drugs
Matchpoint Therapeutics secured $150 million in Series B funding to develop oral small molecule treatments targeting autoimmune and inflammatory diseases.
Matchpoint Therapeutics has closed a $150 million Series B financing round aimed at advancing its pipeline of first-in-class oral small molecule therapies for autoimmune and inflammatory diseases, the company announced via GlobeNewswire.
The capital raise marks a significant vote of confidence in Matchpoint's approach to developing orally administered treatments in a therapeutic area where biologics — typically administered by injection or infusion — have long dominated. Oral small molecules, if proven effective, could offer patients a more convenient alternative and potentially expand access to care.
Read more Michigan Print Shop Wins NRC Contract After SBA Expo Meeting →
Autoimmune and inflammatory diseases represent a broad and commercially significant category, encompassing conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease. The space has attracted sustained investor interest as existing therapies, while effective, carry limitations including high costs, complex administration, and side-effect profiles that leave room for improved options.
Series B rounds of this scale typically position a biopharmaceutical company to advance multiple drug candidates through clinical development, potentially into late-stage trials, though specific pipeline milestones and lead asset details were not elaborated upon in the announcement. The "first-in-class" designation signals that Matchpoint is pursuing novel mechanisms of action rather than competing directly with established drugs.
Continue reading at GlobeNewswire - Industry News on Financial Services.
